PL4025612T3 - Przeciwciała anty-fukozylo-gm1 - Google Patents
Przeciwciała anty-fukozylo-gm1Info
- Publication number
- PL4025612T3 PL4025612T3 PL20767753.5T PL20767753T PL4025612T3 PL 4025612 T3 PL4025612 T3 PL 4025612T3 PL 20767753 T PL20767753 T PL 20767753T PL 4025612 T3 PL4025612 T3 PL 4025612T3
- Authority
- PL
- Poland
- Prior art keywords
- fucosyl
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1912657.2A GB201912657D0 (en) | 2019-09-03 | 2019-09-03 | Binding members |
| PCT/EP2020/074441 WO2021043810A1 (en) | 2019-09-03 | 2020-09-02 | Anti-fucosyl-gm1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4025612T3 true PL4025612T3 (pl) | 2026-04-27 |
Family
ID=68207228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20767753.5T PL4025612T3 (pl) | 2019-09-03 | 2020-09-02 | Przeciwciała anty-fukozylo-gm1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12552876B2 (pl) |
| EP (1) | EP4025612B1 (pl) |
| JP (1) | JP7672395B2 (pl) |
| KR (1) | KR20220054648A (pl) |
| CN (1) | CN114729057B (pl) |
| AU (1) | AU2020340691A1 (pl) |
| BR (1) | BR112022003568A2 (pl) |
| CA (1) | CA3150555A1 (pl) |
| DK (1) | DK4025612T3 (pl) |
| ES (1) | ES3060303T3 (pl) |
| FI (1) | FI4025612T3 (pl) |
| GB (1) | GB201912657D0 (pl) |
| PL (1) | PL4025612T3 (pl) |
| PT (1) | PT4025612T (pl) |
| WO (1) | WO2021043810A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE121C (de) | 1877-08-10 | FISCHER & STIEHL in Essen | Verfahren zur Kühlung und Vorwärmung der Luft mit Hülfe der Erdwärme | |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| AU7757581A (en) | 1980-11-19 | 1982-05-27 | United Energy Technologies Inc. | Enhanced surface tubing |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS5811808A (ja) | 1981-07-16 | 1983-01-22 | Niles Parts Co Ltd | 方位検出表示回路 |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4630115A (en) | 1983-05-09 | 1986-12-16 | The General Electric Company, P.L.C. | Cathode ray tube display device |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| EP1017419A4 (en) | 1997-09-25 | 2004-12-29 | Sloan Kettering Institutefor C | FUCOSYL-GM1-KLH CONJUGATE VACCINE AGAINST SMALL CELL LUNG CANCER |
| US7854934B2 (en) | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| US8383118B2 (en) * | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| US20170247466A1 (en) | 2014-09-25 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of lung cancer using an anti-fucosyl-gm1 antibody |
| MX2023007780A (es) * | 2021-01-08 | 2023-07-10 | Bristol Myers Squibb Co | Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. |
-
2019
- 2019-09-03 GB GBGB1912657.2A patent/GB201912657D0/en not_active Ceased
-
2020
- 2020-09-02 ES ES20767753T patent/ES3060303T3/es active Active
- 2020-09-02 EP EP20767753.5A patent/EP4025612B1/en active Active
- 2020-09-02 PT PT207677535T patent/PT4025612T/pt unknown
- 2020-09-02 KR KR1020227010391A patent/KR20220054648A/ko active Pending
- 2020-09-02 JP JP2022514457A patent/JP7672395B2/ja active Active
- 2020-09-02 CA CA3150555A patent/CA3150555A1/en active Pending
- 2020-09-02 PL PL20767753.5T patent/PL4025612T3/pl unknown
- 2020-09-02 CN CN202080061945.8A patent/CN114729057B/zh active Active
- 2020-09-02 US US17/639,467 patent/US12552876B2/en active Active
- 2020-09-02 DK DK20767753.5T patent/DK4025612T3/da active
- 2020-09-02 FI FIEP20767753.5T patent/FI4025612T3/fi active
- 2020-09-02 WO PCT/EP2020/074441 patent/WO2021043810A1/en not_active Ceased
- 2020-09-02 AU AU2020340691A patent/AU2020340691A1/en active Pending
- 2020-09-02 BR BR112022003568A patent/BR112022003568A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220267466A1 (en) | 2022-08-25 |
| EP4025612B1 (en) | 2025-10-29 |
| DK4025612T3 (da) | 2026-02-02 |
| GB201912657D0 (en) | 2019-10-16 |
| CN114729057B (zh) | 2024-09-03 |
| FI4025612T3 (fi) | 2026-01-30 |
| KR20220054648A (ko) | 2022-05-03 |
| CA3150555A1 (en) | 2021-03-11 |
| PT4025612T (pt) | 2025-12-30 |
| JP7672395B2 (ja) | 2025-05-07 |
| CN114729057A (zh) | 2022-07-08 |
| JP2022546762A (ja) | 2022-11-08 |
| ES3060303T3 (en) | 2026-03-25 |
| AU2020340691A1 (en) | 2022-03-24 |
| EP4025612A1 (en) | 2022-07-13 |
| WO2021043810A1 (en) | 2021-03-11 |
| US12552876B2 (en) | 2026-02-17 |
| WO2021043810A8 (en) | 2025-07-03 |
| BR112022003568A2 (pt) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280780A (en) | Anti-TIGIT antibodies | |
| IL291068A (en) | Anti-cd73 antibodies | |
| IL289112A (en) | Antibodies against tigit | |
| IL280013A (en) | Anti-IL36R antibodies | |
| SG11202108141VA (en) | Novel cd40-binding antibodies | |
| IL279352A (en) | IL-11RA antibodies | |
| GB201905150D0 (en) | Ant-ige antibodies | |
| IL278010A (en) | Antibodies to galectin 10 | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| IL277030A (en) | Antibodies | |
| IL284584A (en) | Anti-tigit antibodies | |
| ZA202108836B (en) | Anti-epha4 antibody | |
| GB2581174B (en) | Antibodies against hEPCR | |
| SG11202102114UA (en) | Anti-klrg1 antibodies | |
| GB201900732D0 (en) | Antibodies | |
| GB201806084D0 (en) | Antibodies | |
| GB201917480D0 (en) | Antibodies | |
| GB201919062D0 (en) | Antibody | |
| SG11201913540VA (en) | Anti-Podoplanin Antibody | |
| IL289160A (en) | Anti-angpt2 antibodies | |
| PL4025612T3 (pl) | Przeciwciała anty-fukozylo-gm1 | |
| GB2598698B (en) | Affinity-maturated anti-ASICIa antibodies | |
| GB201919280D0 (en) | Antibodies | |
| GB201901648D0 (en) | Galectin-10 antibodies | |
| GB201912008D0 (en) | Antibody |